HRP20130906T1 - Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze - Google Patents

Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze Download PDF

Info

Publication number
HRP20130906T1
HRP20130906T1 HRP20130906AT HRP20130906T HRP20130906T1 HR P20130906 T1 HRP20130906 T1 HR P20130906T1 HR P20130906A T HRP20130906A T HR P20130906AT HR P20130906 T HRP20130906 T HR P20130906T HR P20130906 T1 HRP20130906 T1 HR P20130906T1
Authority
HR
Croatia
Prior art keywords
compound
formula
solvent
salt
cinchonidine
Prior art date
Application number
HRP20130906AT
Other languages
English (en)
Croatian (hr)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel DEPRÉ
Véronique CERPENTIER
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of HRP20130906T1 publication Critical patent/HRP20130906T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/475Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20130906AT 2008-12-23 2009-12-22 Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze HRP20130906T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
PCT/EP2009/067715 WO2010072742A1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
HRP20130906T1 true HRP20130906T1 (hr) 2013-10-25

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130906AT HRP20130906T1 (hr) 2008-12-23 2009-12-22 Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze

Country Status (22)

Country Link
US (2) US8927722B2 (cg-RX-API-DMAC7.html)
EP (1) EP2382198B1 (cg-RX-API-DMAC7.html)
JP (1) JP5687631B2 (cg-RX-API-DMAC7.html)
KR (1) KR101734507B1 (cg-RX-API-DMAC7.html)
CN (1) CN102264715B (cg-RX-API-DMAC7.html)
AR (1) AR074863A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009331530B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923393B1 (cg-RX-API-DMAC7.html)
CA (1) CA2745565C (cg-RX-API-DMAC7.html)
CY (1) CY1114488T1 (cg-RX-API-DMAC7.html)
DK (1) DK2382198T3 (cg-RX-API-DMAC7.html)
ES (1) ES2429013T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130906T1 (cg-RX-API-DMAC7.html)
IL (1) IL213246A (cg-RX-API-DMAC7.html)
MX (1) MX2011006764A (cg-RX-API-DMAC7.html)
PL (1) PL2382198T3 (cg-RX-API-DMAC7.html)
PT (1) PT2382198E (cg-RX-API-DMAC7.html)
RU (1) RU2016120007A (cg-RX-API-DMAC7.html)
SI (1) SI2382198T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201300116B (cg-RX-API-DMAC7.html)
TW (1) TWI461424B (cg-RX-API-DMAC7.html)
WO (1) WO2010072742A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072742A1 (en) 2008-12-23 2010-07-01 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
WO2013041655A1 (en) * 2011-09-22 2013-03-28 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
AU2012327934B2 (en) 2011-10-28 2017-06-01 Janssen Pharmaceuticals, Inc. Improved process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
US9090653B2 (en) * 2012-06-08 2015-07-28 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
IN2014MN02652A (cg-RX-API-DMAC7.html) 2012-06-08 2015-08-21 Gilead Sciences Inc
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
AU2014233390B2 (en) 2013-03-15 2018-03-01 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis C virus
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) * 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) * 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) * 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
PT1713823E (pt) * 2004-01-30 2010-02-02 Medivir Ab Inibidores da protease ns-3 da serina do hcv
CN101146794A (zh) * 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
MY139988A (en) * 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
SI2121674T1 (sl) 2007-02-01 2010-09-30 Tibotec Pharm Ltd Postopki in intermediati za pripravo makrocikličnega proteaznega inhibitorja HCV
BRPI0807482A2 (pt) * 2007-02-08 2014-05-13 Tibotec Pharm Ltd Fenilcarbamatos macrocíclicos inibidores de hcv
WO2010072742A1 (en) 2008-12-23 2010-07-01 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Also Published As

Publication number Publication date
TWI461424B (zh) 2014-11-21
CA2745565A1 (en) 2010-07-01
KR101734507B1 (ko) 2017-05-11
CN102264715B (zh) 2015-12-02
US20110257403A1 (en) 2011-10-20
WO2010072742A1 (en) 2010-07-01
KR20110099048A (ko) 2011-09-05
ES2429013T3 (es) 2013-11-12
RU2016120007A (ru) 2018-11-13
SI2382198T1 (sl) 2013-11-29
CY1114488T1 (el) 2016-10-05
US8927722B2 (en) 2015-01-06
BRPI0923393A2 (pt) 2015-07-28
CA2745565C (en) 2017-03-07
MX2011006764A (es) 2011-08-03
AR074863A1 (es) 2011-02-16
US20150080577A1 (en) 2015-03-19
PT2382198E (pt) 2013-10-01
PL2382198T3 (pl) 2013-11-29
DK2382198T3 (da) 2013-09-30
IL213246A0 (en) 2011-07-31
EP2382198B1 (en) 2013-07-10
CN102264715A (zh) 2011-11-30
SMT201300116B (it) 2013-11-08
AU2009331530B2 (en) 2015-04-09
HK1164839A1 (zh) 2012-09-28
AU2009331530A1 (en) 2011-06-23
BRPI0923393B1 (pt) 2018-06-19
IL213246A (en) 2017-10-31
JP5687631B2 (ja) 2015-03-18
RU2011130895A (ru) 2013-01-27
TW201033205A (en) 2010-09-16
US9115077B2 (en) 2015-08-25
EP2382198A1 (en) 2011-11-02
JP2012513381A (ja) 2012-06-14

Similar Documents

Publication Publication Date Title
HRP20130906T1 (hr) Postupci i intermedijeri za pripravu makrocikliäśkog inhibitora hcv proteaze
JP2012513381A5 (cg-RX-API-DMAC7.html)
KR101598135B1 (ko) Hcv의 마크로사이클릭 프로테아제 억제제의 제조 방법 및 중간체
ES2291465T3 (es) Procedimiento para preparar oxazolidinonas.
MX2014009917A (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
RU2742005C2 (ru) Способы получения 4-алкокси-3-(ацил или алкил)оксипиколинамидов
JP2019210273A (ja) エドキサバンの製造方法
JP2017518272A (ja) 置換サイクロセリンの調製のための方法
Sheikh et al. Mechanistic studies of DCC/HOBt-mediated reaction of 3-phenylpropionic acid with benzyl alcohol and studies on the reactivities of ‘active ester’and the related derivatives with nucleophiles
EP2978750B1 (en) "synthesis of dabigatran"
KR20160138538A (ko) 소듐 (2s, 5r)-6-(벤질옥시)-7-옥소-1,6-다이아자바이사이클로[3.2.1]옥테인-2-카복실레이트의 제조 방법
Rho et al. A convenient method for the preparation of alkanolamides
ES2991258T3 (es) Procedimientos y productos intermedios para producir compuestos de diazaespiro-lactama
Liu et al. A facile solid phase synthesis of tetramic acid
CN102775425A (zh) 一种头孢卡品二异丙胺盐的一锅煮制备方法
Szakonyi et al. Mild and efficient ring opening of monoterpene-fused β-lactam enantiomers. Synthesis of novel β-amino acid derivatives
Zych et al. The effect of substitution patterns on the release rates of opioid peptides DADLE and [Leu5]-enkephalin from coumarin prodrug moieties
JP6235473B2 (ja) 大環状hcvプロテアーゼ阻害剤を製造するための方法および中間体
CN104910068A (zh) 一种2-氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法
KR20250017014A (ko) 에독사반 및 이의 토실산염 1수화물의 신규 제조방법
RU2742765C1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
ES2296806T3 (es) Nuevos derivados de cianoril (o cianoheteroaril)-carbonil-piperazini l-pirimidinas, su preparacion y su aplicacion como medeicamentos.
WO2023200364A1 (ru) Способы получения (1r,2s,5s)-n-[(1s)-1-циано-2-[(3s)-2-оксопирролидин-3-ил]этил]-3-[(2s)-3,3-диметил-2-[(2,2,2-трифторацетил)амино]бутаноил]-6,6-диметил-3-азабицикло[3.1.0]гексан-2-карбоксамида
CN101033209B (zh) 药物中间体(2s,4r)-4-羟基-n,n-二甲基-2-吡咯烷甲酰胺的制备方法
ITMI20131677A1 (it) Procedimento per la preparazione di saxagliptina